LncRNA: An all-rounder in rheumatoid arthritis

Junyu Liang, Weiqian Chen, Jin Lin
Division of Rheumatology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China

ABSTRACT

Rheumatoid arthritis (RA) is a chronic autoimmune disease and is supposed to have both genetic and environmental backgrounds. Plenty of studies have demonstrated the roles of long non-coding RNAs (lncRNAs) in the initiation and development of RA. Numerous lncRNAs have been found to be dysregulated in RA and to be correlated with disease activity of RA, which indicates potential diagnostic roles of lncRNAs. In addition to working as biomarkers for RA, lncRNAs participate in many specific pathological processes including inflammation, aberrant proliferation, migration, invasion and apoptosis. Further screenings and researches are required to validate the clinical potentials of lncRNAs as diagnostic and therapeutic targets in RA.

Key words: rheumatoid arthritis, lncRNA, inflammation, tumor-like behavior

INTRODUCTION

Rheumatoid arthritis (RA) is a chronic autoimmune disease featuring persistent synovitis in the joints and systemic inflammation.[1] Approximately 1% of the worldwide population is affected by RA, making it one of the most prevalent autoimmune diseases nowadays.[2] RA can lead to functional decline, disability and loss of productivity as a consequence of joint deformity and pain.[3] Initiation and development of RA is supposed to be influenced by both genetic and environmental factors. It has been postulated that a high-risk genetic background, together with epigenetic elements and environmental exposures, leads to a cascade of events initiating RA.[4] A significant portion of RA patients remain unremitted despite progress in treatment,[5] making it crucial to dig deeper into the molecular mechanisms of RA so as to identify the potential therapeutic target for RA.

Previously recognized as “junk” elements, non-coding RNAs (ncRNAs) and their roles in various biological processes have been widely studied in recent years.[7] The ncRNAs involved in epigenetic mechanisms are divided into two principal subgroups: the long ncRNAs (lncRNAs) with more than 200 nucleotides and small ncRNAs with less nucleotides.[8] And according to the position relative to protein-coding genes, lncRNAs can be further classified into pseudogene lncRNAs, antisense lncRNAs, enhancer RNAs, intronic lncRNAs, and long intergenic noncoding RNAs.[9] To date, thousands of lncRNAs have been identified in human body, and have been shown to control every level of the gene expression. Functions assigned to lncRNAs include transcriptional interference, initiation of chromatin remodeling, promoter inactivation by binding to basal transcription factors, activation of accessory protein, activation and transport of transcription factors, oligomerization of activator protein, and epigenetic repression of genes or gene clusters.[10] Accumulating evidence has shown that lncRNAs participate in the process of inflammation, aberrant proliferation, migration, invasion and apoptosis,[11–14] and their roles in autoimmune diseases, such as systemic lupus erythematosus (SLE), sjogren syndrome, RA, multiple sclerosis, have also been demonstrated by researchers across the world.[15–19]
In this review, we intend to identify numerously dysregulated lncRNAs in RA, discuss their potential roles in disease initiation and progression, and seek to sketch the mediating network of lncRNAs.

**DYSREGULATED EXPRESSION OF LncRNAs IN RA**

The most common approaches to identify RA-related lncRNAs are microarray and qPCR (quantitative real-time Polymerase Chain Reaction). The targeted cells range from peripheral blood cells to fibroblast like synoviocytes (FLSs). Yuan and his colleagues targeted the peripheral blood monocyte cells (PBMCs) and identified 2,099 lncRNAs and 2,307 mRNAs that were differentially expressed between the RA patients and healthy controls (HCs). The qPCR results exhibited that the expressions of ENST00000456270 and NR_002838 were significantly increased in the RA patients, whereas the expressions of NR_026812 and uc001zwf.1 were significantly decreased in comparison to those in HCs.[20] Later exploration revealed that the expression of ENST00000456270 was positively correlated with the serum levels of IL-6, TNF-α as well as the Simplified Disease Activity Index (SDAI) of the RA patients. Luo et al. performed microarray on PBMCs of patients diagnosed with RA and HCs.[21] And they recognized a total of 5,045 lncRNAs (upregulated, 2,410; downregulated, 2,635) and 3,289 mRNAs (upregulated, 1,403; downregulated, 1,886) that were dysregulated in patients with RA. The following lncRNA target prediction revealed the presence of 135 potential lncRNA-mRNA target pairs for the 85 aberrant lncRNAs and 109 aberrant mRNAs.

Zhang et al. used microarray to profile the alterations of lncRNAs in FLSs of tissues isolated from knee joints of RA patients and HCs.[22] 135 lncRNAs were differentially expressed between RA FLSs and HCs. The qPCR data revealed that lncRNA ENST00000483588 was up-regulated and three other lncRNAs (ENST00000456270, uc001zwf.1, and ENST00000452247) were down-regulated in RA FLSs in comparison to those in HCs. Furthermore, the expression level of ENST00000483588 was found to be positively correlated with the level of serum C-reactive protein (CRP) and SDAI. By calculating the areas under the ROC curves of the above lncRNAs, their potential diagnostic value for RA were also proposed. Similar process was also seen in the research on RA rat model. Jiang et al. compared the expression of lncRNAs in FLSs between the RA model rats induced by Freund’s complete adjuvant (FCA) and HCs.[23] Up to 260 lncRNAs were found to be dysregulated in FCA-induced RA model rats. Of those, six dysregulated lncRNAs including XR_008357, U75927, MRAK046251, XR_006457, DQ266363 and MRAK003448 were further validated by qRT-PCR.

lncRNAs proven to play a role in other autoimmune diseases or similar biological processes of other diseases could also be studied in RA. Zhang et al. previously identified two novel lncRNAs, lnc0640 and lnc5150, which played a role in the development of SLE and the effect of lnc0640 and lnc5150 in RA was hereby explored.[24] The expression of lnc0640 in PBMCs of RA patients was significantly increased, whereas the expression of lnc5150 was significantly decreased. And the two lncRNAs were found to be significantly associated with the level of serum CRP. In addition, lnc5150 level was as well associated with erythrocyte sedimentation rate (ESR). Certain SNPs within lnc0640 and lnc5150 were also proved to be linked to RA. LncRNA Gas5 has previously been demonstrated to induce the apoptosis of tumor cells through sponging a number of cancer-related miRNAs, and to exert pro-apoptotic effects in macrophages and endothelial cells to alleviate atherosclerosis.[25,26] Li and his colleagues hereby sought to figure out the role of Gas5 in apoptosis of FLSs in RA patients.[27] And apoptosis of FLSs was found to be induced by Gas5 via activating phosphatidylinositol 3 kinase/protein kinase B (PI3K/AKT) pathway.

**DIVERSE ROLES OF LncRNAs IN PATHOGENESIS OF RA**

**Inflammation**

HOTAIR is an lncRNA that has been widely studied in the development of several diseases including various cancers[28] and cardiovascular disease.[29] In 2014, Song et al. reported a notably elevated expression level of HOTAIR in PBMCs and serum exosome of patients with RA.[30] Besides, over-expressed HOTAIR in exosome help attracting active macrophage into target. However, the expression level of HOTAIR was observed to be significantly decreased in RA FLSs compared to that in HCs. And the enforced expression of HOTAIR alleviated the activation of matrix metalloproteinases MMP-2 and MMP-13. To further validate the role of HOTAIR in RA, Zhang et al. studied the effect of HOTAIR on inflammation in LPS-induced chondrocytes that mimicked the chondrocyte alteration in RA.[31] They identified significant down-regulation of HOTAIR in LPS-induced chondrocytes. Enforced expression of HOTAIR drastically reduced the expression of IL-17 and IL-23, which indicated a protective role of HOTAIR in RA inflammation. Furthermore, the protective mechanism of HOTAIR was found to be associated with the targeted miR-138. An LPS-induced up-regulation of IL-1β, TNF-α and p65 was inhibited by HOTAIR overexpression and the effect can be reversed by miR-
138 mimic transfection. Moreover, the nuclear transfer of p65 was notably inhibited by the overexpression of HOTAIR, which was also partly reversed by miR-138 mimic transfection. Similar results were observed in RA rats as well. A HOTAIR-miR-138-nuclear factor-κB (NF-κB) axis was hereby recognized by going downstream.

LncRNA H19 is located on chromosome 11 in humans and has been proven to play pivotal roles in proliferation, invasion, and metastasis of tumor. Stuhlmueller et al. demonstrated that H19 expression was up-regulated in the synovial tissue (synovial macrophages and fibroblasts in particular) from patients with RA in comparison to HCs. Moreover the expression of H19 could be induced to a higher level in RA FLSs by starvation regardless of the treatment of TNF-α, IL-1β or platelet-derived growth factor-BB (PDGF-BB). And the P13K and mitogen-activated protein kinase-1/2 (ERK-1/2) pathways were reported to mediate starvation-induced H19 expression. These results suggested that H19 might promote RA through P13K and ERK-1/2 pathways. The specific mediating routine in RA remains unexplored.

Lu and his colleagues observed significantly increased expression level of LncRNAs LOC100652951 and LOC100506036 in T cells from patients with RA compared with that in HCs. Moreover, the expression of LOC100652951 within RA T cells was inversely correlated with the treatment of biologic agents including tumor necrosis factor antagonists like abatacept and tocilizumab. Meanwhile, expression of LOC100506036 was inversely correlated with the use of cyclosporine, which revealed its possible correlation with Ca2+-influx-related gene. Elevated expression level of LOC100506036 was also found in the activated Jurkat cells and silencing LOC100506036 reduced the expression of IFN-γ. The expression levels of nuclear factor of activated T cells 1 (NFAT1), which in turn regulates the expression of various cytokines, was drastically decreased after silencing LOC100506036. These findings indicate that LOC100506036 might promote inflammation in T cells of RA patients through activating the transcription of NFAT1.

NTT is located on chromosome 6q23–q24, and is supposed to exert its function via regulating the nearby genes. A research published in 2018 revealed the role of C/EBPβ/NTT/PBOV1 axis in RA. NTT was found to express predominantly in the nucleus and has been proven to play pivotal roles in proliferation, invasion, and metastasis of tumor. Increased level of C/EBPβ was observed to bind to the promoter of NTT and promote NTT expression. By going downstream, the researchers showed that NTT might enhance the expression of PBOV1, which led to THP-1’s cell cycle arrest and differentiation to macrophages, by interacting with hnRNP-U and binding to the promoter of PBOV1. Furthermore, C/EBPβ, NTT, and PBOV1 expression levels within PBMCs were prominently elevated in RA, and were observed to decline after the treatment. Positive correlation between C/EBPβ/NTT/PBOV1 expressions and initial disease activity scores (DAS28) was identified. C/EBPβ expression was also found to be positively correlated with SDAI. These results collectively demonstrate that the C/EBPβ/NTT/PBOV1 axis is significantly activated in untreated RA, and their expression levels might be linked to a higher inflammatory status.

Spurlock et al. probed into the role of lincRNA-p21 in RA via analyzing patients’ blood samples. Lower basal level of lincRNA-p21 and higher basal level of phosphorylated p65 (a NF-κB subunit) were observed in the RA patients compared with those in HCs. MTX was identified to induce the over-expression of lincRNA-p21 through a DNA-dependent protein kinase catalytic subunit-dependent (DNA-PKcs) mechanism in activated T cells and Jurkat cells. Besides, they also found that MTX reduced the NF-κB activity and the following pro-inflammatory effect in TNF-α-treated cell in a lincRNA-p21-dependent manner. In this case, the elevated level of lincRNA-p21 is supposed to play a protective role in RA.

Yang and his colleagues identified that shikonin, a major active ingredient isolated from zicao, inhibited inflammatory response in FLSs of RA mice through lincRNA-NR024118-SOCS3 pathway. SOCS proteins were reported to be induced by cytokines and were found to subsequently act in a negative feedback loop to inhibit cytokine signal transduction. Treatment of shikonin in mice was found to increase the expression of lincRNA-NR024118 and SOCS3, and decreased the expression of inflammatory cytokines and MMPs. In addition, shikonin increased acetylation of H3 at the NR024118 promoter in RA FLSs. Besides, overexpression and silencing of lincRNA-NR024118 increased and decreased the expression of Sox3, respectively. And silencing lincRNA-NR024118 aborted the protective effect of shikonin, which could be recovered by NR024118 interference. The effect of human homologue of lincRNA-NR024118 demands further research.

The TRAF1-C5 region was previously identified to be associated with RA. Increased level of C5 was found in the inflamed joints of RA patients, and C5-deficient mice was proven to be resistant to the development of collagen induced arthritis. Messemaker et al. found that lincRNA C5T1 was associated with the transcription of C5 in the RA patients. In their study, C5T1 lincRNA was found to express predominantly in the nucleus and its expression was correlated positively with C5 mRNA in
various tissues and in peripheral blood mononuclear cells, which indicated potential transcriptional co-regulation. Furthermore, knockdown of lncRNA C5T1 resulted in the decrease of C5 mRNA levels in FLSs, which indicated the potential role of lncRNA C5T1 in RA.

**Proliferation, Migration and Invasion**

Previous studies demonstrated that RA FLSs shared similar features with tumor cells, such as tumor-like migration, invasion, and aberrant proliferation.[46] Increased proliferation, migration and invasion of FLSs has been proven to greatly contribute to RA initiation and progression.[47] In hepatocellular carcinoma, lncRNA ZFAS1 was found to promote cell migration and invasion via sponging miR-150 and inhibiting its tumor-suppressive function.[48] which brought researchers to suspect the role of ZFAS1 in RA. Ye et al. found ZFAS1 expression was increased in RA FLSs compared with that in HCs.[49] Silencing ZFAS1 suppressed RA FLSs’ migration and invasion, while overexpression of ZFAS1 exerted the opposite effect. Further research demonstrated that ZFAS1 directly targeted miR-27a, reduced the expression of miR-27a and promoted RA FLSs’ migration and invasion in a miR-27a-dependent manner.

LncRNA GAPLINC was also reported to promote proliferation, migration, invasion, and metastasis of cancer cells.[50,51] Mo and his colleagues showed a greater level of expression of GAPLINC in RA FLSs than that in FLSs of patients with traumatic injury.[52] Knocking-down GAPLINC ameliorated the morbid proliferation of RA FLSs, as well as migration and invasion. Production of various cytokines and MMPs such as IL-6, IL-8 and MMP-9 was also decreased after the suppression of GAPLINC. Further verification demonstrated that silencing of GAPLINC increased miR-382-5p and miR-575 expression, suggesting GAPLINC might promote proliferation, migration and invasion of RA FLSs via sponging miR-382-5p and miR-575. These results indicated that GAPLINC might promote tumor-like behaviors of RA FLSs in a miR-382-5p-dependent and miR-575-dependent manner.

Aside from the role in inflammation, HOTAIR was also found to influence the proliferation of chondrocytes. Zhang et al. observed the notably increased cell viability and proliferative ability of LPS-induced chondrocytes after enforced expression of HOTAIR.[53] Ki67 and PCNA, as two proliferation-associated markers, were over-expressed as well. Similar results were found in cartilage tissues of RA rats after subcutaneous injection of LV-HOTAIR.

**Apoptosis**

Apoptosis is an important mechanism that regulates tissue composition and homeostasis.[54] In recent years, apoptosis of synovial cells and inflammatory cells has been considered as a therapeutic tool in RA. To date, studies on lncRNAs and apoptosis mainly focus on FLSs.

Urothelial carcinoma associated 1 (UCA1) is a newly-identified lncRNA located on the chromosome 19p13.12. Recent years have seen many progresses in the study of UCA1. YAN et al. found that UCA1 was closely related to rheumatoid arthritis.[54] In this study, UCA1 and caspase-3 were found to be highly expressed in HCs compared with those in RA FLSs. In contrast, cell viability was higher in RA FLSs than in HCs. In addition, knock-down of UCA1 decreased the expression of caspase-3 in HCs, and overexpression of UCA1 increased the expression of caspase-3 within RA FLSs. The opposite happened to cell viability under similar interventions. These results led to the conclusion that UCA1 might play a protective role in RA via inducing apoptosis of FLSs. Furthermore, the authors found that UCA1 suppression in HCs could improve the expression of Wnt6, while UCA1 overexpression in RA FLSs could reduce the expression of Wnt6. And the viability of RA FLSs, which was somehow negatively correlated with apoptosis in this case, recovered after they transfected the over-expressed plasmid of Wnt6 into the UCA1-overexpressed RA FLSs. UCA1 influenced cell viability through altering expression of Wnt6.

Up-regulation of MALAT1 is seen in various human cancers and has been proven to be associated with cancer metastasis and recurrence.[55] Pan et al. observed the elevation of apoptotic rate of RA FLSs after the treatment of quercetin.[56] To figure out the molecular mechanism of the effect of quercetin on RA FLSs, alterations of expression of lncRNAs within the cells were analyzed with the application of PCR array and qPCR. And MALAT1 was found to be the most prominently altered lncRNA in RA FLSs. The knockdown of MALAT1 inhibited the apoptosis of the RA FLSs, decreased the expression of caspase-3, caspase-9 and Bax, and increased the expression of the anti-apoptotic Bel-2 in the cells. The MALAT1 knockdown also promoted the phosphoinositide 3-kinase PI3K/AKT signaling pathway. These findings demonstrated that MALAT1-dependent suppression of the pro-survival PI3K/AKT pathway contributed to FLSs’ apoptosis induced by quercetin.

LncRNA Gas5 was previously found to play a role in the apoptosis of tumor cells, macrophages and endothelial cells.[57,58] A study conducted by researchers from Yangzhou revealed the role of Gas5 in apoptosis of FLSs.[59] Expression of lncRNA Gas5 was found to be down-regulated in RA FLSs in comparison to that in HCs. Besides, the treatment of Tan-IIA, which was supposed to ameliorate RA, aggravated the apoptosis of RA FLSs,
attenuated the viability of RA FLSs and up-regulated Gas5 at the same time. Knockdown of Gas5 afterwards induced lower expression of caspase-3 and caspase-9, ameliorated the apoptosis of RA FLSs, and activated the PI3K/AKT pathway under the treatment of Tan-IIA. Taken together, PI3K/AKT signaling works as a potent pathway of Gas5-mediated FLSs’ apoptosis.

CONCLUSION

The difficulties in early identification and treatment of refractory RA urge researchers to further explore the poorly-understood pathogenic mechanism of RA. Recent years have seen accumulating evidence for mediating roles of lncRNAs in RA, including their influence on inflammation, aberrant proliferation, migration, invasion and apoptosis. And the diagnostic value of lncRNAs, which has long been ignored, is also revealed by the researchers. The numerously identified lncRNAs, the comprehensive effects, and the various pathways in between indicate a mediating network of lncRNAs in the initiation and development of RA (Figure 1). Compared with that in cancer research, the network in RA leaves many gaps to fill in. Future screenings are demanded to identify more lncRNAs and their effect on RA. Further animal studies and subsequent clinical trials are also required to validate the clinical potentials of lncRNAs as therapeutic targets in RA.

Source of Foundation

This study is supported in part by the grants from National Natural Science Foundation of China (81701600) and Natural Science Foundation of Zhejiang Province (LQ17H100001 and LGF18H100001).

Conflict of Interest

None declared.

REFERENCE


Figure 1 Network of LncRNAs in rheumatoid arthritis. (Synoviocyte: H19, NR024118 (mice), ZFAS1, GAPLINC, UCA1, MALAT1, Gas5 (Synoviocyte and HeLa cell); Monocyte: NTT(Monocyte and THP-1), LncRNA C5T1: T cell and Jurkat cell; LOC100506036, LincRNA-p21; Chondrocyte: HOTAIR)
Liang et al.: LncRNA and rheumatoid arthritis


How to cite this article: Liang J, Chen W, Lin J. LncRNA: An all-rounder in rheumatoid arthritis. J Transl Int Med 2019; 7: 3-9.